{
    "clinical_study": {
        "@rank": "67199", 
        "acronym": "LEGEND", 
        "arm_group": {
            "arm_group_label": "Lansoprazole, tablets, orally, once daily for up to 8 weeks"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy of 4-week lansoprazole (Takepron) therapy for subjective\n      symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms"
        }, 
        "brief_title": "Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms", 
        "completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "condition": "Gastroesophageal Reflux Disease With Dyspepsia Symptoms", 
        "condition_browse": {
            "mesh_term": [
                "Dyspepsia", 
                "Gastroesophageal Reflux"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance of lansoprazole (Takepron) with a 4-week\n      observational period, designed to evaluate the efficacy in gastroesophageal reflux disease\n      patients with dyspepsia symptoms (planned sample size, 15000).\n\n      The dosage regimen is as follows:\n\n        -  For reflux esophagitis, the usual adult dosage is 30 mg of lansoprazole administered\n           orally once daily for up to 8 weeks. For maintenance treatment of repeatedly\n           recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole\n           administered orally once daily. If insufficient efficacy is observed, the dosage may be\n           increased to 30 mg administered orally once daily.\n\n        -  For non-erosive gastroesophageal reflux disease, the usual adult dosage is 15 mg of\n           lansoprazole administered orally once daily for up to 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with heartburn or acid regurgitation at the start of Takepron\n             administration* , or patients without heartburn and acid regurgitation, but with\n             endoscopic findings classified as Los Angeles grade A-D at the start of Takepron\n             therapy.\n\n          2. Patients with symptoms of dyspepsia (i.e., postprandial fullness, early satiation,\n             epigastric pain, epigastric burning, upper abdominal bloating, nausea/vomiting, or\n             belching) at the start of Takepron administration* *These patients must have answered\n             \"never, \" \"sometimes/mild,\" \"often/moderate,\" or \"frequent/severe\" on a 4-point scale\n             questionnaire about subjective symptoms.\n\n        Exclusion Criteria:\n\n          1. Patients who have taken any proton pump inhibitors (including Takepron) within 4\n             weeks before the start of Takepron administration\n\n          2. Patients taking antidepressants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Gastroesophageal reflux disease with dyspepsia symptoms"
            }
        }, 
        "enrollment": {
            "#text": "14965", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990339", 
            "org_study_id": "467-531"
        }, 
        "intervention": {
            "arm_group_label": "Lansoprazole, tablets, orally, once daily for up to 8 weeks", 
            "description": "\u2022 Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.\nFor maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.\n\u2022 Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.", 
            "intervention_name": "Lansoprazole", 
            "intervention_type": "Drug", 
            "other_name": "Takepron"
        }, 
        "intervention_browse": {
            "mesh_term": "Lansoprazole"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 21, 2013", 
        "number_of_groups": "1", 
        "official_title": "Takepron Special Drug Use Surveillance \"Gastroesophageal Reflux Disease With Dyspepsia Symptoms\"", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Subjective symptoms will be evaluated as \"Disappeared,\" \"Improved,\" \"No change,\" \"Worsened,\" or \"Unclear.\" At Week 4, the rate of improvement (i.e., the frequency of an evaluation of \"Disappeared\" + \"Improved\") will be calculated for each symptom.", 
            "measure": "Subjective symptom improvement rate", 
            "safety_issue": "No", 
            "time_frame": "Start of treatment and  Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The frequency of adverse drug reactions by type, seriousness and time to onset,. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}